CEO Update - 24 June 2024

UK General Election

In two Newscasts time, we will know the outcome of the UK General Election to be held on Thursday, 4 July. Join our webinar tomorrow at 1pm where we will discuss what we have learned from the campaigns and manifestoes about potential future policies and people important for our sector after the result. I hope this timely summary will give you what you need to be ready for the key change in our ecosystem this summer. Of course, we will also update after the result on the early days of the next government and parliament.

UK Foreign Office supports African Vaccine Manufacturing Accelerator 

Away from the election campaign, Foreign Secretary David Cameron was at the Gavi Investment Opportunity and African Vaccine Manufacturing Accelerator (AVMA) launch in Paris last Thursday. The AVMA is an innovative financial mechanism, designed by Gavi in close collaboration with Africa CDC, to help vaccine manufacturers in Africa and support regional diversification of vaccine manufacturing.

The UK government has pledged the reallocation of £49 million towards AVMA’s launch, as part of Gavi’s successful recovery of COVID-19 funds to enhance vaccine equity and improve global pandemic preparedness. In case you have missed it, the UK is a leading supporter of Gavi. Since its inception, the UK has invested £5.5 billion, helping immunise over a billion of the world’s children and save 17 million lives.

However, I see this as a real missed opportunity for joined-up government and industry working in the UK. There is no connection between this initiative and the great work we are doing on training the next generation of staff needed to successfully run innovative medicines manufacturing, nor engagement with the regulatory regime needed to approve innovative vaccines at scale and pace, let alone overcome the trade barriers of the global supply chain for these types of products. It really feels as if the UK joined upness of the vaccine taskforce days has dissipated since the pandemic and despite well-meaning and strong initiatives the UK is not making the most of the strong and varied ecosystem we have. There is a real opportunity for joined-up leadership after the election.

ARIA call ‘Safeguarded AI’

ARIA (the UK Advanced Innovation and Research Agency) is looking for the next phase of applications for the Safeguarded AI program in early summer.

It’s an open call, where they want to fund teams that can leverage their AI ‘gatekeeper’ workflow to address valuable, high-impact applications of AI that require stronger guarantees of performance than is possible today. The brainy bunch have a thesis on this and are interested in customer/deployment-oriented technology teams who see value in safeguarding autonomous AI systems or providing critical decision-support tools in a variety of high-value/impact applications e.g. energy system optimisation; infectious disease epidemiology; climate and weather prediction; aircraft and spaceflight dynamics; and control systems for robots in human environments. They are also open to new ideas.

Cross the academic/industry threshold with the Royal Society Entrepreneurs in Residence scheme

Apply now to the 2024 round of the Royal Society Entrepreneurs in Residence scheme. The grant provides opportunities for enthusiastic, highly experienced industrial scientists and entrepreneurs to spend one day a week at a university developing a bespoke project that will:

  1. Expose university staff and students to state-of-the-art industrial research and development, and the scientific challenges faced by industry
  2. Provide support and expert advice aimed at promoting innovation and the translation of research by Universities
  3. Grow confidence in and understanding of business and entrepreneurship among staff and students
  4. Provide career recognition to the award holders and support their professional development.

As an Entrepreneur in Residence, successful applicants will also join a network of like-minded individuals across the UK (including me, who learnt a lot from this scheme in the last couple of years). Application deadline is 18 September 2024.

...and finally, monkey business

It’s nearing the end of exam season so I’m setting a challenge to BIA members (well, probably, the IP lawyers amongst you) to answer this conundrum thrown up by a high-profile piece of research in the news last week. Did you see this study, which was announced by Oxford University and reported in the global media that observed chimpanzees as they sought out and discovered plants with medicinal properties?

So the exam question is: if chimps can now help scientists find plants that have the potential to become medicines and observing primates paves the way for new drug discoveries, how does the Nagoya protocol apply? Do the chimpanzees play an active or passive role in the research here?

(They may have led the researchers to study a given plant, but a journal article could theoretically have led researchers to study the same. The knowledge itself pre-physical access of the genetic resource does not trigger ABS obligations.)

But under the new WIPO patent disclosure requirement and treatment of associated traditional knowledge – do the chimpanzees hold associated traditional knowledge? Or is it the humans who first observed them? Or the Western researchers who documented that in a research journal? Would a biotech company seeking patent from any such discovery have to disclose the chimpanzees as the traditional knowledge community in their patent application that resulted from ‘using’ this knowledge? And would the case be the same if the Chimps were observed in a zoo or safari park in the UK?

Bottle of champagne and blog post on the BIA website to whoever comes up with the best answer to that!

Don't miss our upcoming events this summer - we hope to see you there!


Steve Bates Headshot.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

CEO Update - 8 July 2024

It is a fantastic way to start the week with news of Europe’s largest Series A biotech spin-out this year from the UK. Congratulations to Myricx Bio, an Imperial College London and Francis Crick Institute spin-out company focusing on a novel class of payloads for antibody-drug conjugates (ADCs), for announcing their Series A financing of £90 million.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Brandon Capital's vision for a transcontinental life science axis

Jonathan Tobin, Partner at Brandon Capital, discusses the firm's recent close of its sixth fund at A$270 million, bringing its total assets under management to over A$1.25 billion. He also explores how Brandon Capital is strategically connecting Australia, New Zealand, the UK, and the US.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

PIR International interview with Anja Harmeier, CEO, Rewind Therapeutics

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

More within